| Zoledronic Acid | Novartis | ||
| EQ 4MG BASE/5ML Injectible |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
| None |
Less Than 5
|
||
|
More Than 5
|
More Than 5
|
||
| Hypercalcemia Of Malignancy, Multiple Myeloma And Bone Metastases Of Solid Tumors, | |||
|
Yes
| |||
| Zoledronic Acid | None | ||
| EQ 4MG BASE/100ML |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
| None |
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | |||
|
No
| |||
| Zometa | Patent 1 |
|---|---|
| ***** ****** | ******* *** ********* |
| ****** | ******* *** ********* |
| *** ****** | ******* *** ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** ****** | *** \ ** | -**- | ******* *** ********* *** **** **** | ******** | ******** ** **** *, **** / ******** ** *** *, **** |
| ****** | ** \ ** | -**- | ******* *** ********* | ******** | *** ****** ******* |
| *** ****** | ** \ ** | -**- | ******* *** ********* | ********* ******** | *** ****** **** ******** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|